Citations

Clear

634 citation(s) found for "Hall, A".

Radiological Society of North America/Quantitative Imaging Biomarker Alliance Shear Wave Speed Bias Quantification in Elastic and Viscoelastic Phantoms
Palmeri, Mark L. , Milkowski, Andy , Barr, R. Graham , Carson, Paul L. , Couade, Mathieu , Chen, Shigao , Dhyani, Manish , Ehman, Richard L. , Garra, Brian S. , Gee, Albert, Guenette, Gilles, Hah, Zaegyoo , Lynch, Ted , Macdonald, Michael , Managuli, Ravi , Nightingale, Kathryn R. , Obuchowski, Nancy A. , Rouze, Ned C. , Morris, D. Cody , Fielding, Shana, Chan, Derek Y. , Choudhury, Kingshuk Roy , Yang, Siyun , Shamdasani, Vijay, Wear, Keith A. , Xie, Hua , Qiang, Bo, Rosenzweig, Stephen, Okamura, Yoko, McLaughlin, Glen, Chen, Yuling , Napolitano, David , Carlson, Lindsey , Erpelding, Todd N. , Barr, Richard , Carson, Paul , Dhyani, Manish , Ehman, Richard , Hah, Zaegyoo , Lynch, Ted , Macdonald, Michael , Managuli, Ravi , Miette, Veronique , Nightingale, Kathryn R , Obuchowski, Nancy , Rouze, Ned C , Morris, D Cody , Deng, Yufeng , Chan, Derek , Choudhury, Kingshuk , Samir, Anthony E , Urban, Matthew W , Wear, Keith , Ozturk, Arinc , Song, Pengfei , McAleavey, Stephen , Napolitano, David , Carlson, Lindsey , Hall, Timothy J , Chen, Jun , Miette, Véronique , Urban, Matthew W. , Song, Pengfei , Wang, Michael , Hall, Timothy J.

Mayo Clinic

Journal of Ultrasound in Medicine | January 10, 2021 | Volume: 40 | Issue: 3 | Pages: 569-581

10.1002/jum.15609 | PMID 33410183 Get It

ObjectivesTo quantify the bias of shear wave speed (SWS) measurements between different commercial ultrasonic shear elasticity systems and a magnetic resonance elastography (MRE) system in elastic and viscoelastic phantoms.MethodsTwo elastic phantoms, representing healthy through fibrotic liver, were measured with 5 different ultrasound platforms, and 3 viscoelastic phantoms, representing healthy through fibrotic liver tissue, were measured with 12 different ultrasound platforms. Measurements were performed with different systems at different sites, at 3 focal depths, and with different appraisers. The SWS bias across the systems was quantified as a function of the system, site, focal depth, and appraiser. A single MRE research system was also used to characterize these phantoms using discrete frequencies from 60 to 500 Hz.ResultsThe SWS from different systems had mean difference 95% confidence intervals of ±0.145 m/s (±9.6%) across both elastic phantoms and ± 0.340 m/s (±15.3%) across the viscoelastic phantoms. The focal depth and appraiser were less significant sources of SWS variability than the system and site. Magnetic resonance elastography best matched the ultrasonic SWS in the viscoelastic phantoms using a 140 Hz source but had a − 0.27 ± 0.027‐m/s (−12.2% ± 1.2%) bias when using the clinically implemented 60‐Hz vibration source.ConclusionsShear wave speed reconstruction across different manufacturer systems is more consistent in elastic than viscoelastic phantoms, with a mean difference bias of < ±10% in all cases. Magnetic resonance elastographic measurements in the elastic and viscoelastic phantoms best match the ultrasound systems with a 140‐Hz excitation but have a significant negative bias operating at 60 Hz. This study establishes a foundation for meaningful comparison of SWS measurements made with different platforms.
NCCN Guidelines Insights: Acute Myeloid Leukemia, Version 2.2021
Altman, Jessica K. , Assi, Rita, Bachiashvili, Kimo, Fathi, Amir T. , Fedorov, Kateryna, Foran, James M. , Gojo, Ivana , Goldberg, Aaron, Hall, Aric C. , Jonas, Brian A., Levine, Matthew R., Mangan, James, Mannis, Gabriel N. , Marcucci, Guido , Moriarty, Kelsey, Ali, Moaath Mustafa, Neff, Jadee , Nejati, Reza , Olin, Rebecca L. , Patel, Anand, Percival, Mary‐Elizabeth M. , Perl, Alexander E. , Pettit, Kristen, Rao, Dinesh S. , Ravandi‐Kashani, Farhad, Schwabkey, Zaker, Shallis, Rory, Stahl, Maximilian, Stone, Richard M. , Thota, Swapna, Uy, Geoffrey L., Walker, Alison, Wang, Eunice, Awotiwon, Ajibola, Roth, Sydney L., Stehman, Katie, Strickland, Stephen A. , Przespolewski, Amanda , Strickland, Stephen Anthony , Pollyea, Daniel Aaron , Assi, Rita, Bachiashvili, Kimo, Bhatt, Vijaya Raj , Fedorov, Kateryna, Goldberg, Aaron, Jonas, Brian A., Levine, Matthew R., Mangan, James, Mims, Alice S , Moriarty, Kelsey, Ali, Moaath Mustafa, Patel, Anand, Pettit, Kristen, Schwabkey, Zaker, Shallis, Rory, Stahl, Maximilian, Thota, Swapna, Uy, Geoffrey L., Walker, Alison, Wang, Eunice, Awotiwon, Ajibola, Roth, Sydney L., Stehman, Katie

Mayo Clinic

Journal of the National Comprehensive Cancer Network | January 6, 2021 | Volume: 19 | Issue: 1 | Pages: 16-27

10.6004/jnccn.2021.0002 | PMID 33406488 Get It

The NCCN Guidelines for Acute Myeloid Leukemia (AML) provide recommendations for the diagnosis and treatment of adults with AML based on clinical trials that have led to significant improvements in treatment, or have yielded new information regarding factors with prognostic importance, and are intended to aid physicians with clinical decision-making. These NCCN Guidelines Insights focus on recent select updates to the NCCN Guidelines, including familial genetic alterations in AML, postinduction or postremission treatment strategies in low-risk acute promyelocytic leukemia or favorable-risk AML, principles surrounding the use of venetoclax-based therapies, and considerations for patients who prefer not to receive blood transfusions during treatment.
Consensus Statement for Pharmacological Management of Coronavirus Disease 2019 (COVID-19): A Pragmatic Approach
Javeri, Yash , Ak, Khanna, AA, Tayar, BG, Jagiasi, JLP, Portilla, Zirpe, Kapil , Ka, Popugaev, MLNG, Malbrain, Ma, Kirkman, MTV, Chan, Mer, M, Harriss, Mohammed, Rangappa, Pradeep, Piacevoli, Q, Mani, RK, Rc, Mishra, Bagdia, S, Donovan, Suzanne, ST, Reza, TY, Yeh, Videtta, Walter , R, Jain, Nasa, Prashant , Kashyap, Rahul , Bhaskar, Balu , Jagiasi, Bharat G , Juneja, Deven , Lipman, Jeffrey , J, Ng, Hashmi, Madiha , Türkoğlu, Melda , M, Singer, Garg, Rakesh Kumar , Yadav, Rakesh Kumar , TY, Yeh

Mayo Clinic

Asploro Journal of Biomedical and Clinical Case Reports | December 28, 2020 | Volume: 3 | Issue: 3 | Pages: 241-256

10.36502/2020/asjbccr.6219 Get It

Introduction: In the absence of high-quality evidence for Coronavirus disease-2019 (COVID-19), supportive care is advocated during this pandemic. We aim to develop a consensus statement from global experts for pharmacological management, based on the pathophysiology of COVID-19. Material and Methods: We used a modified Delphi methodology in three steps: 1) Formulation of the steering committee and questionnaire; 2) Delphi methodology and selection of experts; 3) Final meeting of the steering committee and analysis, discussion, preparation, and presentation of captured data. Results: 34 (73·9%) experts accepted the invitation for the study. We conducted two rounds of Delphi and consensus (>70% votes) was achieved on 11 out of 24 statements after the end of round two. Conclusion: This global consensus suggests that “Anti-viral therapy should be administered in the early infection phase of COVID-19 followed by low dose steroid therapy in pulmonary phase. Prophylactic dose anticoagulation should be used in hospitalized, mild to moderate COVID-19 patients. We make no suggestions for the use of immune modulation therapy”.
Ultrasound in Trauma and Other Acute Conditions in Sports, Part II
Ray, Jeremiah W. , Gende, Alecia, Hall, Mederic M. , Coe, Ian, Situ-LaCasse, Elaine , Waterbrook, Anna L., Gende, Alecia M

Mayo Clinic

Current Sports Medicine Reports | December 10, 2020 | Volume: 19 | Issue: 12 | Pages: 546-551

10.1249/jsr.0000000000000788 | PMID 33306518 Get It

Abstract The utility of ultrasound in sports medicine is improving the sports medicine physician's ability to rapidly diagnose and treat a multitude of sports related pathologies. In this article, we clearly outline the current status of the evidence in support of using sports ultrasound in the setting of acute ocular injury, evaluation of elevated intracranial pressures, deep venous thrombosis, and soft tissue complaints.
Detection of Bacteremia with Liquid Media Containing Sodium Polyanetholsulfonate
Hall, M M, Warren, Edward, Washington, John A., Warren, Edward

Mayo Clinic

Applied Microbiology | December 5, 2020 | Volume: 27 | Issue: 1 | Pages: 187-191

10.1128/am.27.1.187-191.1974 | PMID 4358860 Get It

Two liquid blood culture media, Tryptic soy broth (TSB) and Thiol broth, containing sodium polyanetholsulfonate were compared in 8,654 cultures. Pseudomonas and Corynebacterium (including Propionibacterium ) were isolated significantly more frequently ( P < 0.001) from TSB than from Thiol. Escherichia coli, Haemophilus , and Bacteroidaceae were isolated more frequently in TSB; however, the differences were not statistically significant. In no instance was Thiol superior to TSB in detecting bacteremia. In an additional 2,977 cultures, aerobic and anaerobic Vacutainer culture tubes with supplemented peptone broth were inoculated in parallel with TSB and Thiol. Significantly greater rates of detection ( P < 0.01) in TSB or Thiol were noted with Pseudomonas, E. coli, Enterobacter , viridans, and group A streptococci, Bacteroidaceae, and staphylococci.
Comparison of Two Liquid Blood Culture Media Containing Sodium Polyanetholesulfonate: Tryptic Soy and Columbia
Hall, M M, Warren, Edward, Washington, John A., Warren, Edward

Mayo Clinic

Applied Microbiology | December 5, 2020 | Volume: 27 | Issue: 4 | Pages: 699-702

10.1128/am.27.4.699-702.1974 | PMID 4596751 Get It

In a comparison of tryptic soy broth and Columbia broth, two blood culture media containing sodium polyanetholesulfonate, there were 589 positive cultures (excluding presumed contaminants). The two media were equivalent in performance except for lower detection rates for Staphylococcus aureus ( P < 0.01) and Pseudomonas aeruginosa ( P = 0.05) and a higher detection rate for Bacillus ( P < 0.01) in Columbia broth. No significant differences were noted in time intervals to detection of positivity. Routine subcultures on the 1st and 5th days of incubation provided the initial detection of 18.1% of the positive cultures.
Klebsiella, Enterobacter , and Serratia : Biochemical Differentiation and Susceptibility to Ampicillin and Three Cephalosporin Derivatives
Zabransky, R.J., Hall, Jack W., Day, Fred E., Needham, Gerald M.

Mayo Clinic

Applied Microbiology | December 5, 2020 | Volume: 18 | Issue: 2 | Pages: 198-203

10.1128/am.18.2.198-203.1969 | PMID 4896880 Get It

Three hundred twenty-nine strains of the tribe Klebsielleae were compared by several biochemical tests and by susceptibility to selected antibiotics. Biochemical tests included urease, amino acid decarboxylase, and hydrogen sulfide production; fermentation of lactose and dextrose; motility; and tests in the IMViC (indole, methyl red, Voges-Proskauer, citrate) series. The isolates were: Klebsiella species, 67.5%; Enterobacter species, 28%, and Serratia species, 4.5%. Minimal inhibitory concentrations of cephaloridine, cephalothin, and a new cephalosporin, cephalexin, and of ampicillin were determined by the agar dilution procedure. Cephalosporins at 20 μg/ml or less inhibited 90% of the Klebsiella strains but only 15% of the Enterobacter strains. Ampicillin inhibited 27% of Enterobacter strains and 17% of Klebsiella strains. Serratia isolates were insensitive to the cephalosporins and ampicillin. The results suggest that precise identification of this group to the generic level can be accomplished readily in the clinical laboratory and that such information is helpful in the preliminary selection of an antibiotic for treatment of clinical infections.
HGG-18. CLINICAL EFFICACY OF ONC201 IN THALAMIC H3 K27M-MUTANT GLIOMA
Chi, Andrew , Kurz, Sylvia C. , Wen, Patrick Y. , Arrillaga‐Romany, Isabel , Batchelor, Tracy T. , Butowski, Nicholas , Shonka, Nicole , DeGroot, John, Hall, Matthew D. , Daghistani, Doured , Schwartz, Jonathan , Cartaxo, Rodrigo T. , Siada, Ruby , Miklja, Zachary , Bruzek, Amy K., Wierzbicki, Kyle , Paul, Alyssa , Wolfe, Ian, Leaoard, Marcia, Garton, Hugh , Mody, Rajen , Robertson, Patricia L. , Merdinger, Krystal, Venneti, Sriram , Oster, Wolfgang, Allen, Joshua E. , Kawakibi, Abed Rahman , Tarapore, Rohinton S. , Gardner, Sharon L , Wen, Patrick Yung , Arrillaga‐Romany, Isabel , Sumrall, Ashley , Harrison, Rebecca A , Mehta, Minesh P. , Odia, Yazmín , Cloughesy, Timothy F. , Ellingson, Benjamin M. , Umemura, Yoshie , Yadav, Viveka Nand , Cantor, Evan , Lu, Guangrong , Koschmann, Carl

Mayo Clinic

Neuro-Oncology | December 4, 2020 | Volume: 22 | Issue: Supplement_3 | Pages: iii347-iii347

10.1093/neuonc/noaa222.305 Get It

Abstract ONC201, a bitopic DRD2 antagonist and allosteric ClpP agonist, has shown encouraging efficacy in H3 K27M-mutant glioma. Given that the thalamus has the highest extra-striatal expression of DRD2, we performed an integrated preclinical and clinical analysis of ONC201 in thalamic H3 K27M-mutant glioma. ONC201 was effective in mouse intra-uterine electroporation (IUE)-generated H3 K27M-mutant gliomas, with an in vitro IC50 of 500 nM and 50% prolongation of median survival in vivo (p=0.02, n=14). We analyzed thalamic H3 K27M-mutant glioma patients treated with ONC201 on active clinical trials as of 5/22/19 enrollment (n=19 recurrent and 10 post-radiation, non-recurrent; 5–70 years old). As of 12/18/2019, PFS6 and OS12 are 26.3% and 36.8%, respectively, in the recurrent group. For non-recurrent patients, with median follow up of 21.9 months (8.6–26.6) from diagnosis, median PFS or OS have not been reached. This surpasses historical OS of 13.5 months. Best response by RANO includes 1 CR, 3 PR, 4 SD, 8 PD for recurrent patients and 2 PR, 4 SD, 1 PD for non-recurrent patients (4 on-trial patients experienced regressions that are yet unconfirmed responses). Median duration of response for recurrent patients is 14.0 months (2.0–33.1). Furthermore, H3 K27M cell-free tumor DNA in plasma and CSF correlated with MRI response. In summary, single agent ONC201 administered at recurrence, or adjuvantly following radiation, demonstrates promising clinical efficacy in thalamic H3 K27M-mutant glioma patients who currently have no effective treatments following radiation. Investigations are ongoing to assess whether micro-environmental DRD2 expression explains the early exceptional responses in thalamic H3 K27M-mutant glioma.
Abstract 14500: Physical Activity in Individuals With the Long Qt Syndrome: Baseline Data From the Lifestyle and Exercise in Long Qt Study (live Lqts)
Lampert, Rachel , Day, Sharlene M. , Marino, Bradley S. , Burg, Matthew M. , Ainsworth, Barbara E. , Etheridge, Susan P. , Aziz, Peter F. , Czosek, Richard J. , Erickson, Christopher C. , Gray, Belinda , Johnsrude, Christopher L. , McClellan, Rebecca , Shah, Maully, Webster, Gregory G, Simone, Laura, Barth, Cheryl , Harmon, Kim S, Olshansky, Brian , Estes, Mark, Tomaselli, Gordon F., Saarel, Elizabeth V. , Cannom, David S. , Ackerman, Michael J. , Olshansky, Brian , Johnsrude, Christopher , Gray, Belinda , Tome, Maite , Abrams, Dominic J. , Cerrone, Marina , Kannankeril, Prince J. , Law, Ian H. , Molossi, Silvana M , Pérez, Marco , Sanatani, Shubhayan , Shah, Maully J. , Skinner, Jonathan R. , Ware, James S. , Webster, Gregory G, Li, Fangyong , Hall, Kevin D. , Link, Mark S.

Mayo Clinic

Circulation | November 12, 2020 | Volume: 142 | Issue: Suppl_3 | Pages: No page available

10.1161/circ.142.suppl_3.14500 Get It

Introduction: The safety of vigorous exercise for individuals with appropriately-treated LQTS remains unproven, and physical activity practices in this population have not been described. Methods: LIVE-LQTS prospectively enrolled individuals age 8-60 years with overt LQTS or gene mutation carriers. Participants (or parents, for children) answered surveys describing activity patterns. Vigorous exercise was defined as > 6 METS for > 60 hours per year. Clinical and demographic data were derived from medical record review. Results: Among 1554 participants, 804 (52%) reported exercising vigorously, 473 of these competitively, 577 (37%) exercising at moderate, and 173 (11%) at low levels. Seven percent of those working describe jobs more active than walking, including 10 in protective services and 19 in sports/coaching. Over 90% are genotype positive, 57% are phenotype positive at rest and an additional 16% have exercise-induced QT prolongation. Forty four percent have had documented ventricular arrhythmias or syncope. Eighty-four percent are appropriately treated with either beta-blockers, ICD, and/or sympathectomy, although among beta-blocked patients, only 60% are on the most effective agents. Among adults, BMI was significantly lower among the vigorous exercisers. Conclusion: While the high percentage of vigorous exercisers seen in this study may not represent all patients with LQTS due to self-selection for study participation, many patients with LQTS are engaged in vigorous exercise or competitive athletics. Prospective follow up of this cohort is ongoing and will determine safety of vigorous exercise through comparison of arrhythmic outcomes in vigorous exercisers vs moderate/low level exercisers.